Andarix appoints experts to help in the development of P2045

08/1/2011 | PR Web

Andarix Pharmaceuticals has appointed new clinical oncology experts to its clinical advisory board to help with the development of its lead drug candidate, P2045. The drug is a treatment for lung and other cancers and is based on a radiolabeled somatostatin peptide analogue.

View Full Article in:

PR Web

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA